Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 65Neoplasm Metastasis 56Leukemia, Myeloid, Acute 55Multiple Myeloma 44Prostatic Neoplasms 43Melanoma 43Lung Neoplasms 39Colorectal Neoplasms 36Lymphoma 33Pancreatic Neoplasms 31Leukemia, Lymphocytic, Chronic, B-Cell 30Carcinoma, Non-Small-Cell Lung 29Myelodysplastic Syndromes 26Squamous Cell Carcinoma of Head and Neck 25Lymphoma, Large B-Cell, Diffuse 25Triple Negative Breast Neoplasms 22Neoplasms 22Ovarian Neoplasms 21Burkitt Lymphoma 21Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Carcinoma, Renal Cell 18Sarcoma 17Lymphoma, Mantle-Cell 17Glioma 17Uterine Cervical Neoplasms 16Rectal Neoplasms 16Leukemia, Myelomonocytic, Chronic 15Fallopian Tube Neoplasms 15Stomach Neoplasms 14

Interventions

Gemcitabine 25Cisplatin 18Carboplatin 10Paclitaxel 9Specimen Handling 6Nivolumab 6Doxorubicin 6Docetaxel 6pembrolizumab 5Magnetic Resonance Spectroscopy 5cabozantinib 4avelumab 4Vinblastine 4Radiotherapy 4Methotrexate 4Fluorouracil 4enfortumab vedotin 3atezolizumab 3aflibercept 3Trastuzumab 3Sunitinib 3Ramucirumab 3Platinum 3Ipilimumab 3Immunoglobulin G 3Disulfides 3CTLA-4 Antigen 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3vinflunine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Urethral Neoplasms × Biopsy × Clear all
NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
152 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡